Safety of PCI-32765 in Chronic Lymphocytic Leukemia

NCT01105247 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: PCI-32765

Sponsor

Pharmacyclics LLC.